Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer

Inclusion criteria

• .Lung cancer confirmed by histology and/or cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after multidisciplinary team (MDT) discussion.
• The clinical staging based on positron emission tomography(PET)-computer tomography(CT) examination is: cT1~3 N0M0, stage IA-IIB (AJCC eighth edition).
• Age: 18 years and above.
• Karnofsky(KPS) score ≥60.
• The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.
• Relatively good organ function:
• Normal bone marrow function: white blood cell (WBC)≥3×109/L, Platelet ≥80×109/L, Hemoglobin(HGB)≥90g/L
• Normal liver and kidney function:
• Total bilirubin, Aspartate Aminotransferase(AST), and ALT(Alanine Aminotransferase)≤2.0×upper limit of normal values;
• Creatinine clearance ≥60ml/min or creatinine ≤1.5×upper limit of normal value
• The patient has signed an informed consent form and is willing and able to comply with planned study visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

• Patients with other malignant tumors.
• Poorly controlled heart failure, respiratory failure, heart function, and lung function below grade 3 (including grade 3).
• Those whose laboratory test values do not meet relevant standards before enrollment.
• Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons.
• Women of childbearing age who have a positive pregnancy test and women who are breastfeeding.
• Patients considered inappropriate for inclusion by other investigators.